Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141469

Published: 2020

Journal Articles

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Ada Dona', PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y. Krishnan, MD, Matt Coffey, PhD, Douglas W. Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, PhD

Blood (2019) 134 (Supplement_1): 1816.

https://doi.org/10.1182/blood-2019-128740

Published: 2019

Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, Tracy Stiller, MS, Joycelynne Palmer, PhD, James F Sanchez, PhD, Xochiquetzal Martinez, MD, Steven Rosen, MD, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 4024.

https://doi.org/10.1182/blood-2019-126358

Published: 2019

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

Targeted Marrow Radiation (TMI) Improves Therapeutic Efficacy of STAT3 Decoy Molecules By Augmenting Its Delivery and Immune Modulation in an AML Mouse Model

Srideshikan Sargur Madabushi, PhD, Darren Zuro, Yu-Lin SU, PhD, Paresh Vishwasrao, MSc, Jamison Brooks, B.S, Liliana E Parra, James F Sanchez, PhD, Jeffrey Wong, MD, Marcin Kortylewski, PhD, Susanta Hui, PhD, DABR.

Blood (2019) 134 (Supplement_1): 3929.

https://doi.org/10.1182/blood-2019-127470

Published: 2019

Journal Articles

Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia

Ibrahim Aldoss, MD, Dongyun Yang, PhD, Raju Pillai, MD, James F Sanchez, PhD, Ahmed Aribi, MD, Haris Ali, MD, Karamjeet S Sandhu, MD, Monzr Al Malki, MD, Matthew Mei, MD, Amandeep Salhotra, MD, Samer K. Khaled, MD, Ryotaro Nakamura, MD, Weili Sun, MD PhD, Margaret R O'Donnell, MD, David S Snyder, MD, Anthony S. Stein, MD, Stephen J Forman, Guido Marcucci, Vinod A. Pullarkat, MD

Blood (2018) 132 (Supplement 1): 334.

https://doi.org/10.1182/blood-2018-99-113670

Published: 2018

Journal Articles

CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Emine Gulsen Gunes, PhD, Hadas Lewinsky, Domenico Viola, Enrico Caserta, Michael Rosenzweig, Myo Htut, James F Sanchez, PhD, Ralf Buettner, PhD, Guido Marcucci, Jonathan J Keats, PhD, Amrita Krishnan, MD, Steven T Rosen, Idit Shachar, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2018-99-119655

Published: 2018

Journal Articles

Immune Mediated Mechanisms of Resistance to Daratumumab

Domenico Viola, Ada Dona, Emine Gulsen Gunes, PhD, Estelle Troadec, Xiwei Wu, Sergio Branciamore, Tinisha McDonald, MS, Lucy Ghoda, PhD, Ashish Streatfield, James F Sanchez, PhD, Chatchada Karanes, Myo Htut, Michael Rosenzweig, Jonathan J Keats, PhD, Steven T Rosen, Guido Marcucci, Amrita Krishnan, MD, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2018-99-117441

Published: 2018

Journal Articles

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Amrita Krishnan, Prashant Kapoor, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Shaji Kumar, MD, Sagar Lonial, MD FACP, Myo Htut, MD, Chatchada Karanes, MD, Nitya Nathwani, MD, Michael Rosenzweig, MD, Firoozeh Sahebi, MD, George Somlo, MD FACP, Lupe Duarte, CTA, Stephen J. Forman, MD, James F Sanchez, PhD, Jesus G. Berdeja, MD

Blood (2016) 128 (22): 3316.

https://doi.org/10.1182/blood.V128.22.3316.3316

Published: 2016

Journal Articles

The miRNA Profile of Cutaneous T Cell Lymphoma Correlates with the Dysfunctional Immunophenotype of the Disease

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, James F Sanchez, PhD, Joycelynne M. Palmer, PhD, Azadeh Motevalli, PhD, Jasmine Zain, MD, Steven T. Rosen, MD

Blood (2016) 128 (22): 4132.

https://doi.org/10.1182/blood.V128.22.4132.4132

Published: 2016

Journal Articles

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Amrita Y. Krishnan, MD, Joycelynne Palmer, PhD, Auayporn P. Nademanee, MD, Robert Chen, Leslie L. Popplewell, MD, Nicole Tsai, MS, James F. Sanchez, PhD, Jennifer Simpson, Ricardo Spielberger, MD, Dave Yamauchi, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 3179.

https://doi.org/10.1182/blood.V126.23.3179.3179

Published: 2015

NARROW

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Targeted Marrow Radiation (TMI) Improves Therapeutic Efficacy of STAT3 Decoy Molecules By Augmenting Its Delivery and Immune Modulation in an AML Mouse Model

Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia

CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Immune Mediated Mechanisms of Resistance to Daratumumab

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

The miRNA Profile of Cutaneous T Cell Lymphoma Correlates with the Dysfunctional Immunophenotype of the Disease

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only